Sepsis: A Market in Need
Executive Summary
In this era of health care reform, critical care medicine remains a strong market for innovative technologies that can improve patient outcomes, shorten ICU stays, and ultimately reduce the overall cost of care. Within this space, one segment that is ripe for innovation is the market for severe sepsis products.Although the last 20 years have seen advances in treatment and a marked increase in the understanding of sepsis and septic shock, severe sepsis remains one of the most significant challenges in critical care today.
You may also be interested in...
New Foley-Based Monitor For Early Detection Of Sepsis
Consano Medical is moving closer to FDA clearance for its Canary Catheter, a novel, continuous monitoring device that leverages an existing urinary catheter for the early detection of sepsis – a serious condition that costs hospitals more than $20 billion annually in the US alone.
Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future
Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?
The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb
Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.